# eIF4E-IN-2

| | |
|---|---|
| **Cat. No.:** | HY-145262 |
| **CAS No.:** | 2575840-38-7 |
| **Molecular Formula:** | $C_{37}H_{33}ClF_2N_8O_4S_2$ |
| **Molecular Weight:** | 791.29 |
| **Target:** | Eukaryotic Initiation Factor (eIF) |
| **Pathway:** | Cell Cycle/DNA Damage |
| **Storage:** | Powder -20°C 3 years<br>4°C 2 years<br>In solvent -80°C 6 months<br>-20°C 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 50 mg/mL (63.19 mM; Need ultrasonic)

**Preparing Stock Solutions**

| Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.2638 mL | 6.3188 mL | 12.6376 mL |
| 5 mM | 0.2528 mL | 1.2638 mL | 2.5275 mL |
| 10 mM | 0.1264 mL | 0.6319 mL | 1.2638 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

eIF4E-IN-2 is a potent inhibitor of eukaryotic initiation factor 4e (eIF4e). eIF4E-IN-2 has the potential for researching eIF4e dependent diseases, including the research of cancer (extracted from patent WO2021003157A1, compound 1188)[1]. eIF4E-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

**$IC_{50}$ & Target**

eIF4

## REFERENCES

[1]. Samuel Sperry, et al. Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds. Patent WO2021003157A1.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA